SL Science Holding Limited was incorporated in the Cayman Islands on March 18, 2025 as an exempted company limited by shares. The company operates through its subsidiaries and focuses on the development of cell and gene therapies, including Armed-T and Gamma Delta T cell technologies and exosomal applications. Its business model is centered on cooperation with biopharmaceutical companies. The company is in the pre-clinical development stage and has not yet received FDA approval for any product candidate. 

SL Science (SLBT) shares dropped 19.54% intraday. The decline follows reminders that its GDT exosome drug submission lacks FDA approval, with candidates still in preclinical stages. Additionally, investors face potential dilution risks as up to 1.04 million shares held by selling shareholders become eligible for resale after their lock-up expires in December 2026.

SL Science (SLBT) Falls 19.54% Amid Regulatory and Dilution Concerns

Chinese Taiwan stocks fell in regular trading, with Ydes down 8.3%, SLBT sliding 17.3% and MKDW falling 15.7%.

Chinese Taiwan stocks rose in after-hours trading after foreign investors reversed prior selling trends with net purchases, supported by tempered Fed rate hike fears and domestic fiscal stimulus, with SLBT up 4.2%, MKDW gaining 1.8% and APWC rising 1.5%.

Chinese Taiwan stocks fell in intraday trading, with Advantech down 3.8%, Silergy sliding 3.9% and Microsemi dropping 7.6%.

SL Science Holding Limited celebrated its first quarter as a public company by ringing the Nasdaq bell. The Taiwanese biomedical firm advanced its gamma delta T cell platform across scientific, academic, and regulatory fronts. Key milestones include ongoing orphan drug designation for Vdelta2+ gamma delta T cells in glioblastoma multiforme and preclinical research at the World Congress of Basic and Clinical Pharmacology. The company's gamma delta T cell platform is licensed from JY BioMed for brain and pancreatic cancer indications, offering a scalable cell population that complements other immunotherapies.

SLBT News